Phase II study of the addition of darbepoetin alfa (Aranesp) and pegfilgrastim (Neulasta) support for optimal dose-dense chemotherapy for early breast cancer
Phase 2
- Conditions
- Breast CancerCancer - Breast
- Registration Number
- ACTRN12605000731695
- Lead Sponsor
- Mater Adult hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- Female
- Target Recruitment
- 30
Inclusion Criteria
Histologically confirmed operable stage IIA, IIB, or IIIA adenocarcinoma of the breast.No prior treatment other than surgery is permitted.
Exclusion Criteria
No exclusion criteria
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method